2423675
Project Grant
Overview
Grant Description
SBIR Phase I: Liquid biopsy diagnostic for early detection of ovarian cancer targeting novel extracellular vesicle biomarkers.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project focuses on advancing a novel ovarian cancer (OC) diagnostic to enhance patient outcomes significantly.
This initiative introduces a pioneering method for identifying biomarkers within extracellular vesicles (EVs), early markers specific to cancer circulating in the bloodstream.
By targeting cancer EVs in a minimally invasive blood test, the project aims for unprecedented sensitivity and specificity in early detection.
Success in this endeavor could pave the way for adapting the approach to develop diagnostics for other cancer types.
The global market for OC diagnostics, currently valued at $1.3 billion and growing at an annual rate of 7%, reflects increasing incidence rates in younger populations and a growing emphasis on early detection strategies.
A successful outcome from this project would position any resulting products favorably in the broader landscape of cancer detection technologies.
This Small Business Innovation Research (SBIR) Phase I project aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancers (OC) by assaying relevant biomarkers on circulating extracellular vesicles (EVs) in patient plasma.
EVs provide significant advantages in sensitivity and patient outcomes over tests using circulating tumor cells or cell-free tumor DNA, as they are secreted by living cancer cells within the primary tumor.
This project will utilize a novel technology to identify key proteins in EVs from various OC subtypes, engineering an assay to differentiate between patients with malignant tumors and those without cancer with high specificity.
The second objective is to employ a machine learning tool to perform diagnostic classification, providing actionable information to clinicians regarding the presence of a tumor.
Successful completion of these objectives will facilitate the development and validation of scalable workflows for the diagnostic assay during Phase II, with the goal of having a laboratory-developed test ready for commercialization by the end of Phase II.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project focuses on advancing a novel ovarian cancer (OC) diagnostic to enhance patient outcomes significantly.
This initiative introduces a pioneering method for identifying biomarkers within extracellular vesicles (EVs), early markers specific to cancer circulating in the bloodstream.
By targeting cancer EVs in a minimally invasive blood test, the project aims for unprecedented sensitivity and specificity in early detection.
Success in this endeavor could pave the way for adapting the approach to develop diagnostics for other cancer types.
The global market for OC diagnostics, currently valued at $1.3 billion and growing at an annual rate of 7%, reflects increasing incidence rates in younger populations and a growing emphasis on early detection strategies.
A successful outcome from this project would position any resulting products favorably in the broader landscape of cancer detection technologies.
This Small Business Innovation Research (SBIR) Phase I project aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancers (OC) by assaying relevant biomarkers on circulating extracellular vesicles (EVs) in patient plasma.
EVs provide significant advantages in sensitivity and patient outcomes over tests using circulating tumor cells or cell-free tumor DNA, as they are secreted by living cancer cells within the primary tumor.
This project will utilize a novel technology to identify key proteins in EVs from various OC subtypes, engineering an assay to differentiate between patients with malignant tumors and those without cancer with high specificity.
The second objective is to employ a machine learning tool to perform diagnostic classification, providing actionable information to clinicians regarding the presence of a tumor.
Successful completion of these objectives will facilitate the development and validation of scalable workflows for the diagnostic assay during Phase II, with the goal of having a laboratory-developed test ready for commercialization by the end of Phase II.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Diego,
California
92121-7703
United States
Geographic Scope
Single Zip Code
Beken Bio was awarded
Project Grant 2423675
worth $275,000
from National Science Foundation in August 2024 with work to be completed primarily in San Diego California United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Liquid Biopsy Diagnostic for Early Detection of Ovarian Cancer Targeting Novel Extracellular Vesicle Biomarkers
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project focuses on advancing a novel ovarian cancer (OC) diagnostic to enhance patient outcomes significantly. This initiative introduces a pioneering method for identifying biomarkers within extracellular vesicles (EVs), early markers specific to cancer circulating in the bloodstream. By targeting cancer EVs in a minimally invasive blood test, the project aims for unprecedented sensitivity and specificity in early detection. Success in this endeavor could pave the way for adapting the approach to develop diagnostics for other cancer types. The global market for OC diagnostics, currently valued at $1.3 billion and growing at an annual rate of 7%, reflects increasing incidence rates in younger populations and a growing emphasis on early detection strategies. A successful outcome from this project would position any resulting products favorably in the broader landscape of cancer detection technologies.
This Small Business Innovation Research (SBIR) Phase I project aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancers (OC) by assaying relevant biomarkers on circulating extracellular vesicles (EVs) in patient plasma. EVs provide significant advantages in sensitivity and patient outcomes over tests using circulating tumor cells or cell-free tumor DNA, as they are secreted by living cancer cells within the primary tumor. This project will utilize a novel technology to identify key proteins in EVs from various OC subtypes, engineering an assay to differentiate between patients with malignant tumors and those without cancer with high specificity. The second objective is to employ a machine learning tool to perform diagnostic classification, providing actionable information to clinicians regarding the presence of a tumor. Successful completion of these objectives will facilitate the development and validation of scalable workflows for the diagnostic assay during Phase II, with the goal of having a laboratory-developed test ready for commercialization by the end of Phase II.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 8/27/24
Period of Performance
8/15/24
Start Date
7/31/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2423675
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
LJJ9XNCRE9L7
Awardee CAGE
8QSG4
Performance District
CA-51
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 8/27/24